Pfizer has finalized the sale of its entire holding in Haleon , generating approximately 2.5 billion ($3.24 billion), Reuters ...

We suggest that investors who own GSK's stock remain invested for now, considering its sales and profits are expected to continue improving in the coming years.

GSK divested Haleon, its consumer group, in July 2022. Given the strong valuations of consumer healthcare companies, we expect this unit will yield a stronger valuation than what was implied ...

With Pfizer’s final stake sale in the bag, the two Big Pharma companies behind Haleon’s genesis have formally parted ways with the standalone consumer health giant. | After charting similar moves ...

GSK's consumer health spinout Haleon started trading on the London Stock Exchange this morning, making its debut with a price of 330 pence and a market valuation of around £31 billion ($37 billion).

Direct-to-consumer Genetic DNA Tests Market Size and ForecastThe Direct-to-consumer (DTC) genetic DNA testing market has ...

The rebrand comes after GSK transferred its consumer health business to Haleon to focus on innovative drugs. Haleon will now encompass consumer health brands including Sensodyne, Panadol, Eno, and ...

Harvey Jones has spotted signs of life in the GSK share price. Which is a relief after its recent troubles, so can the FTSE ...

We recently published a list of the 7 Most Undervalued Biotech Stocks To Invest In. In this article, we are going to take a ...

The U.S. Food and Drug Administration has granted approval to a new antibiotic to treat urinary tract infections in women and ...

Pete Petersen, 58, has been looking for work since last February after he was laid off from his corporate job, suspecting ...